381 related articles for article (PubMed ID: 25608973)
21. Development of scoliosis in young children with osteogenesis imperfecta undergoing intravenous bisphosphonate therapy.
Kashii M; Kanayama S; Kitaoka T; Makino T; Kaito T; Iwasaki M; Kubota T; Yamamoto T; Ozono K; Yoshikawa H
J Bone Miner Metab; 2019 May; 37(3):545-553. PubMed ID: 30187275
[TBL] [Abstract][Full Text] [Related]
22. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
[TBL] [Abstract][Full Text] [Related]
23. Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate.
Cheung MS; Glorieux FH; Rauch F
J Bone Miner Res; 2009 Apr; 24(4):669-74. PubMed ID: 19063679
[TBL] [Abstract][Full Text] [Related]
24. Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age.
Alcausin MB; Briody J; Pacey V; Ault J; McQuade M; Bridge C; Engelbert RH; Sillence DO; Munns CF
Horm Res Paediatr; 2013; 79(6):333-40. PubMed ID: 23735642
[TBL] [Abstract][Full Text] [Related]
25. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome.
Munns CF; Rauch F; Travers R; Glorieux FH
J Bone Miner Res; 2005 Jul; 20(7):1235-43. PubMed ID: 15940378
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of a Modified Pamidronate Protocol for the Treatment of Osteogenesis Imperfecta.
Palomo T; Andrade MC; Peters BS; Reis FA; Carvalhaes JT; Glorieux FH; Rauch F; Lazaretti-Castro M
Calcif Tissue Int; 2016 Jan; 98(1):42-8. PubMed ID: 26387692
[TBL] [Abstract][Full Text] [Related]
27. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment.
Land C; Rauch F; Munns CF; Sahebjam S; Glorieux FH
Bone; 2006 Oct; 39(4):901-6. PubMed ID: 16730480
[TBL] [Abstract][Full Text] [Related]
28. Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta.
Land C; Rauch F; Glorieux FH
J Bone Miner Res; 2006 Mar; 21(3):374-9. PubMed ID: 16491284
[TBL] [Abstract][Full Text] [Related]
29. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
DiMeglio LA; Ford L; McClintock C; Peacock M
Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
[TBL] [Abstract][Full Text] [Related]
30. Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy.
Arikoski P; Silverwood B; Tillmann V; Bishop NJ
Bone; 2004 Mar; 34(3):539-46. PubMed ID: 15003801
[TBL] [Abstract][Full Text] [Related]
31. Cyclic pamidronate therapy in children with osteogenesis imperfecta.
Salehpour S; Tavakkoli S
J Pediatr Endocrinol Metab; 2010; 23(1-2):73-80. PubMed ID: 20432809
[TBL] [Abstract][Full Text] [Related]
32. Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta.
Rauch F; Cornibert S; Cheung M; Glorieux FH
Bone; 2007 Apr; 40(4):821-7. PubMed ID: 17223617
[TBL] [Abstract][Full Text] [Related]
33. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
Löwing K; Aström E; Oscarsson KA; Söderhäll S; Eliasson AC
Acta Paediatr; 2007 Aug; 96(8):1180-3. PubMed ID: 17578486
[TBL] [Abstract][Full Text] [Related]
34. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age.
Plotkin H; Rauch F; Bishop NJ; Montpetit K; Ruck-Gibis J; Travers R; Glorieux FH
J Clin Endocrinol Metab; 2000 May; 85(5):1846-50. PubMed ID: 10843163
[TBL] [Abstract][Full Text] [Related]
35. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta.
Falk MJ; Heeger S; Lynch KA; DeCaro KR; Bohach D; Gibson KS; Warman ML
Pediatrics; 2003 Mar; 111(3):573-8. PubMed ID: 12612238
[TBL] [Abstract][Full Text] [Related]
36. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
[TBL] [Abstract][Full Text] [Related]
37. Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution.
Alharbi M; Pinto G; Finidori G; Souberbielle JC; Guillou F; Gaubicher S; Le Merrer M; Polak M
Horm Res; 2009 Jan; 71(1):38-44. PubMed ID: 19039235
[TBL] [Abstract][Full Text] [Related]
38. Alendronate treatment in children with osteogenesis imperfecta.
Akcay T; Turan S; Guran T; Bereket A
Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
[TBL] [Abstract][Full Text] [Related]
39. Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta.
Aström E; Magnusson P; Eksborg S; Söderhäll S
Acta Paediatr; 2010 Dec; 99(12):1834-40. PubMed ID: 20726960
[TBL] [Abstract][Full Text] [Related]
40. Intravenous pamidronate therapy in osteogenesis imperfecta: response to treatment and factors influencing outcome.
Bajpai A; Kabra M; Gupta N; Sharda S; Ghosh M
J Pediatr Orthop; 2007 Mar; 27(2):225-7. PubMed ID: 17314651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
